Therapy Area
Subcutaneous drugs grant a new lease on life to checkpoint inhibitors
The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approval of Roche’s subcutaneous formulation of Tecentriq.
Yale and Transcend wins US DoD grant for PTSD therapy
GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
EC grants approval for Menarini’s breast cancer therapy
BeiGene agrees with Novartis for global rights to TEVIMBRA
